

Olga Zheliabina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4978515/publications.pdf>

Version: 2024-02-01

19
papers

45
citations

1936888

4
h-index

1872312

6
g-index

19
all docs

19
docs citations

19
times ranked

10
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of the risk of developing type 2 diabetes mellitus in patients with gout based on the FINDRISD ₂ scale. <i>Diabetes Mellitus</i> , 2022, 24, 521-528.	0.5	1
2	Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 52-59.	0.1	4
3	Rational use of recommendations for urate-lowering therapy: clinical examples. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 85-90.	0.1	5
4	Contributing factors of diabetes mellitus among patients with gout (results of the long-term) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	0.2	5
5	Colchicine for the treatment of COVID-19: short path from theory to practice. <i>Meditsinskiy Sovet</i> , 2022, , 71-79.	0.1	0
6	Comparison of the efficacy and safety of various anti-inflammatory drugs in urate-lowering therapy initiation in patients with gout (preliminary data). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 50-56.	0.1	6
7	Advantages of the use of metformin in patients with impaired uric acid metabolism. <i>Terapevticheskii Arkhiv</i> , 2021, 93, .	0.2	2
8	Impact of urate-lowering therapy on quality of life indicators in patients with gout. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 62-68.	0.1	4
9	The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 81-85.	0.1	0
10	Colchicine for acute arthritis attacks prevention in patients with gout during urate-lowering therapy (results of a pilot study). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 50-55.	0.1	2
11	Calcification of coronary arteries in patients with calcium pyrophosphate crystal deposition disease and knee osteoarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 411-417.	0.2	1
12	Cervical vertebrae affection in calcium pyrophosphate crystal deposition disease (description of a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	0.1	1
13	The prevalence of subclinical atherosclerosis of carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 33-38.	0.1	0
14	Type 2 diabetes mellitus and gout. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 599-607.	0.2	2
15	Association of the Q141K polymorphism of the ABCG2 gene with the effectiveness of urate-lowering therapy in patients with gout (a pilot study). <i>Sovremennaya Revmatologiya</i> , 2021, 15, 55-60.	0.1	0
16	The effect of therapy on subclinical atherosclerosis of the carotid arteries in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis (pilot study). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 708-714.	0.2	1
17	Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 76-83.	0.1	1
18	Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. <i>Diabetes Mellitus</i> , 2020, 23, 349-356.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 512-519.	0.2	5